Jim Cramer and our other experts discuss oil prices, bullish market signals and medical diagnostic plays.
TheStreet spoke with John Carreyrou, a reporter with The Wall Street Journal, who brought to light Theranos' issues in a bombshell article in 2015.
Welcome to the future of healthcare. That future includes the use of AI to improve patient outcomes.
These three "strong buy" biotech stocks are primed for outsized growth in the next 12 months. Here's why.
After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.
Valeant will become Bausch Health Cos. this summer. Here's what that could mean for the company as it continues to recover from controversy.
Japan's biggest drugmaker, Takeda Pharmaceutical Co., looks to have wrapped up its bid to buy Dublin-based Shire plc for $62.4 billion in cash and shares.
Jim Cramer and our other experts look at Estee Lauder, 'special dividends' and oncology stocks.
Jim Cramer and our other experts discuss tech stock Skyworks, Buffett's Apple move, and possible Biotech M&A's.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.